Radiological semantics discriminate clinically significant grade prostate cancer
暂无分享,去创建一个
Robert Gillies | Yoganand Balagurunathan | Julio M. Pow-Sang | Sebastian Feuerlein | Hong Lu | R. Gillies | J. Pow-Sang | S. Feuerlein | Qian Li | Y. Balagurunathan | K. Gage | Hong Lu | Qian Li | Jung Choi | Kenneth Gage | Jung W Choi
[1] Paul Kinahan,et al. Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.
[2] Andrew B Rosenkrantz,et al. Radiologist, be aware: ten pitfalls that confound the interpretation of multiparametric prostate MRI. , 2014, AJR. American journal of roentgenology.
[3] A. Villers,et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. , 2006, The Journal of urology.
[4] Pierre Mozer,et al. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. , 2015, European urology.
[5] Adam T Froemming,et al. Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. , 2016, Radiology.
[6] Aytekin Oto,et al. Benign Conditions That Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation. , 2016, Radiographics : a review publication of the Radiological Society of North America, Inc.
[7] H. Hricak,et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference , 2016, European Radiology.
[8] Clare Allen,et al. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy , 2010, BJU international.
[9] Katarzyna J Macura,et al. Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. , 2016, European urology.
[10] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[11] Angela Mariotto,et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.
[12] S. Letautiene,et al. The role of different PI-RADS versions in prostate multiparametric magnetic resonance tomography assessment , 2017, Acta medica Lituanica.
[13] Hiroshi Honda,et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: Correlation with stepwise histopathology , 2008, Journal of magnetic resonance imaging : JMRI.
[14] A. Heidenreich. Consensus criteria for the use of magnetic resonance imaging in the diagnosis and staging of prostate cancer: not ready for routine use. , 2011, European urology.
[15] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.
[16] Rebecca L. Siegel Mph,et al. Cancer statistics, 2018 , 2018 .
[17] J. Richenberg. PI-RADS: past, present and future. , 2016, Clinical radiology.
[18] A. Viera,et al. Understanding interobserver agreement: the kappa statistic. , 2005, Family medicine.
[19] Aytekin Oto,et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. , 2010, Radiology.
[20] Marcus D. Ruopp,et al. Youden Index and Optimal Cut‐Point Estimated from Observations Affected by a Lower Limit of Detection , 2008, Biometrical journal. Biometrische Zeitschrift.
[21] Matthew R Cooperberg,et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[23] Zixiang Xiong,et al. Normalization Benefits Microarray-Based Classification , 2006, EURASIP J. Bioinform. Syst. Biol..
[24] Yu Xuan Kitzing,et al. An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines , 2017, Insights into Imaging.
[25] C. Tempany,et al. MR imaging in adenocarcinoma of the prostate: interobserver variation and efficacy for determining stage C disease. , 1992, AJR. American journal of roentgenology.
[26] Andre Dekker,et al. Radiomics: the process and the challenges. , 2012, Magnetic resonance imaging.
[27] P. Albers,et al. Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard , 2013, European Radiology.
[28] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[29] H. Thoeny,et al. Prostate MRI based on PI-RADS version 2: how we review and report , 2016, Cancer Imaging.
[30] Gary Liney,et al. Correlation of diffusion‐weighted magnetic resonance data with cellularity in prostate cancer , 2009, BJU international.
[31] B. Carey,et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. , 2011, European urology.
[32] P. Lambin,et al. Machine Learning methods for Quantitative Radiomic Biomarkers , 2015, Scientific Reports.
[33] Mladen A. Vouk,et al. Analysis of Free Energy Signals Arising from Nucleotide Hybridization Between rRNA and mRNA Sequences during Translation in Eubacteria , 2006, EURASIP J. Bioinform. Syst. Biol..
[34] Baris Turkbey,et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.
[35] Su-Jin Shin,et al. PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer. , 2017, AJR. American journal of roentgenology.
[36] Raj Persad,et al. Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? , 2013, Journal of magnetic resonance imaging : JMRI.
[37] P. Carroll,et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. , 2004, Radiology.
[38] D. Holdstock. Past, present--and future? , 2005, Medicine, conflict, and survival.
[39] J. Hardenberg,et al. Precision of MRI/ultrasound-fusion biopsy in prostate cancer diagnosis: an ex vivo comparison of alternative biopsy techniques on prostate phantoms , 2017, World Journal of Urology.
[40] J. Sim,et al. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. , 2005, Physical therapy.
[41] Samuel H. Hawkins,et al. Reproducibility and Prognosis of Quantitative Features Extracted from CT Images. , 2014, Translational oncology.
[42] Tae Heon Kim,et al. Diffusion-weighted magnetic resonance imaging for prediction of insignificant prostate cancer in potential candidates for active surveillance , 2015, European Radiology.
[43] Marco Salvatore,et al. Comparison Between Gleason Score and Apparent Diffusion Coefficient Obtained from Diffusion-Weighted Imaging of Prostate Cancer Patients , 2013, Cancer investigation.
[44] B. Jereczek-Fossa,et al. The Utility of Diffusion Weighted Imaging (DWI) Using Apparent Diffusion Coefficient (ADC) Values in Discriminating Between Prostate Cancer and Normal Tissue , 2014, Polish journal of radiology.
[45] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.